A Systematic Review and Meta-Analysis: Lactobacillus acidophilus for Treating Acute Gastroenteritis in Children.
Haixin ChengYi MaXiaohui LiuChao TianXuli ZhongLi-Bo ZhaoPublished in: Nutrients (2022)
The efficacy of probiotic strains of Lactobacillus acidophilus to manage acute gastroenteritis in children is still not established. We searched the Cochrane Library, PubMed, EMBASE, and three Chinese literature databases (CNKI, WanFang, and CBM) from their inception to February 2021 for RCTs that compared the use of Lactobacillus acidophilus with no Lactobacillus acidophilus . The grey literature was searched through Google Scholar. Authors of the original papers were contacted for additional data. The study included a total of 15 RCTs involving 1765 patients. Compared with placebo or no treatment, Lactobacillus acidophilus was associated with a reduced duration of diarrhea (moderate quality of evidence), but the effect was not statistically significant when only the individual probiotic strain was provided. Lactobacillus acidophilus was effective when used at a daily dose ≥ 10 9 CFU. There was no difference in the effect of Lactobacillus acidophilus on diarrhea duration among Asian, European, or American countries. Lactobacillus acidophilus reduced the frequency of diarrhea on day 2 to day 5. However, it was statistically significant on day 3. When administered at a dosage of more than 10 9 CFU to children with acute gastroenteritis, moderate- to low-quality data showed that Lactobacillus acidophilus reduced the duration of diarrhea and conferred a benefit for frequency of diarrhea.
Keyphrases
- lactic acid
- irritable bowel syndrome
- end stage renal disease
- young adults
- big data
- chronic kidney disease
- escherichia coli
- newly diagnosed
- ejection fraction
- machine learning
- multiple sclerosis
- clinical trial
- electronic health record
- high intensity
- intensive care unit
- prognostic factors
- hepatitis b virus
- drug induced
- patient reported outcomes
- aortic dissection
- artificial intelligence
- phase iii
- double blind